loading page

COVID-19 in patients with seizures: considerations for therapeutic management and potential drug-drug interactions
  • +2
  • Shreshta Jain,
  • Heidrun Potschka,
  • P Prarthana Chandra,
  • Manjari Tripathi,
  • Divya Vohora
Shreshta Jain
Jamia Hamdard

Corresponding Author:[email protected]

Author Profile
Heidrun Potschka
Ludwig-Maximilians-Universitat Munchen
Author Profile
P Prarthana Chandra
Hamdard Institute of Medical Science and Research
Author Profile
Manjari Tripathi
All India Institute of Medical Sciences
Author Profile
Divya Vohora
Jamia Hamdard
Author Profile


In regard to the global pandemic of COVID-19, it seems that persons with epilepsy (PWE) are not more vulnerable to get infected by SARS-CoV-2, nor are they more susceptible to a critical course of the disease. However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19. Repurposing of several licensed and investigational drugs is discussed for therapeutic management of COVID-19. While for none of these approaches, efficacy and tolerability has been confirmed yet in sufficiently powered and controlled clinical studies, testing is ongoing with multiple clinical trials worldwide. Here, we have summarized the possible mechanisms of action of drugs currently considered as potential therapeutic options for COVID-19 management along with possible and confirmed drug-drug interactions that should be considered for a combination of antiseizure drugs and COVID-19 candidate drugs.